tiprankstipranks
Trending News
More News >

Sinovac Announces Privy Council Ruling on Board Election

Story Highlights
  • Sinovac Biotech Ltd. is a Chinese biopharmaceutical company specializing in vaccines.
  • A Privy Council ruling confirmed a new board election, impacting Sinovac’s governance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sinovac Announces Privy Council Ruling on Board Election

Confident Investing Starts Here:

Sinovac Biotech ( (SVA) ) has provided an announcement.

On January 16, 2025, Sinovac Biotech Ltd. announced a Privy Council judgment validating the election of a new board proposed by shareholders during the 2018 Annual General Meeting. The ruling invalidates the company’s Rights Agreement and is set to become effective after a court order. Sinovac’s outgoing board is committed to a smooth transition, emphasizing the company’s history of significant shareholder value creation, highlighted by its substantial contribution to the global COVID-19 vaccine effort with 2.9 billion doses delivered worldwide.

More about Sinovac Biotech

Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines. The company’s product portfolio includes vaccines for COVID-19, hepatitis A, influenza, and polio, among others. Sinovac has played a significant role in the global COVID-19 pandemic response with its CoronaVac® vaccine, which is approved in over 60 countries.

YTD Price Performance: 0.0%

Average Trading Volume: 8,227

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $460.3M

Find detailed analytics on SVA stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1